NasdaqGM - Delayed Quote USD

EyePoint Pharmaceuticals, Inc. (EYPT)

16.75 +0.59 (+3.65%)
At close: April 26 at 4:00 PM EDT
16.75 0.00 (0.00%)
After hours: April 26 at 4:20 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
46,018.00
46,018.00
41,404.00
36,939.00
34,437.00
Cost of Revenue
4,632.00
4,632.00
8,326.00
8,177.00
5,824.00
Gross Profit
41,386.00
41,386.00
33,078.00
28,762.00
28,613.00
Operating Expense
116,453.00
116,453.00
112,016.00
84,038.00
65,903.00
Operating Income
-75,067.00
-75,067.00
-78,938.00
-55,276.00
-37,290.00
Net Non Operating Interest Income Expense
5,702.00
5,702.00
-1,058.00
-5,206.00
-7,199.00
Other Income Expense
-1,347.00
-1,347.00
-22,258.00
2,065.00
-905.00
Pretax Income
-70,712.00
-70,712.00
-102,254.00
-58,417.00
-45,394.00
Tax Provision
83.00
83.00
--
--
--
Net Income Common Stockholders
-70,795.00
-70,795.00
-102,254.00
-58,417.00
-45,394.00
Diluted NI Available to Com Stockholders
-70,795.00
-70,795.00
-102,254.00
-58,417.00
-45,394.00
Basic EPS
-1.82
-1.82
-2.74
-2.03
-3.54
Diluted EPS
-1.82
-1.82
-2.74
-2.03
-3.54
Basic Average Shares
38,904.00
38,904.00
37,317.00
28,758.00
12,836.00
Diluted Average Shares
38,904.00
38,904.00
37,317.00
28,758.00
12,836.00
Total Operating Income as Reported
-75,067.00
-75,067.00
-99,637.00
-55,276.00
-37,290.00
Total Expenses
121,085.00
121,085.00
120,342.00
92,215.00
71,727.00
Net Income from Continuing & Discontinued Operation
-70,795.00
-70,795.00
-102,254.00
-58,417.00
-45,394.00
Normalized Income
-69,730.87
-69,730.87
-79,996.00
-60,482.00
-44,489.00
Interest Income
6,949.00
6,949.00
2,131.00
292.00
58.00
Interest Expense
1,247.00
1,247.00
3,189.00
5,498.00
7,257.00
Net Interest Income
5,702.00
5,702.00
-1,058.00
-5,206.00
-7,199.00
EBIT
-69,465.00
-69,465.00
-99,065.00
-52,919.00
-38,137.00
EBITDA
-69,001.00
-69,001.00
-96,619.00
-50,148.00
-35,488.00
Reconciled Cost of Revenue
4,168.00
4,168.00
7,930.00
7,866.00
5,635.00
Reconciled Depreciation
464.00
464.00
2,446.00
2,771.00
2,649.00
Net Income from Continuing Operation Net Minority Interest
-70,795.00
-70,795.00
-102,254.00
-58,417.00
-45,394.00
Total Unusual Items Excluding Goodwill
-1,347.00
-1,347.00
-22,258.00
2,065.00
-905.00
Total Unusual Items
-1,347.00
-1,347.00
-22,258.00
2,065.00
-905.00
Normalized EBITDA
-67,654.00
-67,654.00
-74,361.00
-52,213.00
-34,583.00
Tax Rate for Calcs
0.00
0.00
--
--
--
Tax Effect of Unusual Items
-282.87
-282.87
--
--
--
12/31/2020 - 1/27/2005

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

OCUL Ocular Therapeutix, Inc.
4.7450
+12.98%
 
APLS Apellis Pharmaceuticals, Inc.
49.86
+4.03%
 
DAWN Day One Biopharmaceuticals, Inc.
14.92
+12.94%
 
ALXO ALX Oncology Holdings Inc.
16.86
-0.06%
 
AKRO Akero Therapeutics, Inc.
19.74
+4.28%
 
BHVN Biohaven Ltd.
38.97
+1.12%
 
NKTX Nkarta, Inc.
6.87
+0.73%
 
CLRB Cellectar Biosciences, Inc.
3.0300
+0.33%
 
ACRV Acrivon Therapeutics, Inc.
8.46
-0.12%
 
ALT Altimmune, Inc.
7.26
+0.83%